|Videos|May 27, 2020

CMSC 2020 Day 2: Anthony Feinstein, MPhil, PhD, on Diagnosing and Treating Depression in MS

Anthony Feinstein, MPhil, PhD, FRCP, presents his lecture titled, "Depression and MS: Diagnosing and Treating" as part of the 2020 CMSC Virtual Annual Meeting.

For more coverage from CMSC 2020, click here.

To register for the 2020 CMSC Virtual Annual Meeting, May 26-29, 2020, click here.

To complete the evaluation and claim credit, go to www.highmarksce.com/mscare. Create a new account or log in with your user name and password. Select the Enduring Materials tab, then select the activity from the listing and follow the instructions to complete the activity and receive your credit.

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Related to this article

October 5th, 2026

Ecopipam Shows Early and Sustained Tic Reduction in New Pediatric Tourette Syndrome Analyses

New analyses from the D1AMOND clinical program found that 69.8% of participants achieved a clinically meaningful reduction in tic severity within 8 weeks of ecopipam treatment, while an interim 18-month analysis showed sustained improvement without new safety signals.

October 4th, 2026

Phase 3 PROPEL Trial to Test Imeroprubart in Generalized Myasthenia Gravis

PROPEL will test imeroprubart, an investigational FcRn blocker, against placebo in adults with mild to severe generalized myasthenia gravis.

October 3rd, 2026

Early Spinal Muscular Atrophy Treatment Tied to Milder Pediatric Phenotype

New data from a Cure SMA survey showed that children treated with disease-modifying therapy soon after birth walk more often and have fewer comorbidities than those treated later.

October 3rd, 2026

Nipocalimab’s Safety Profile Slightly Favored Over Other Myasthenia Gravis Therapies, Indirect Comparison Shows

A new Bayesian network meta-analysis found nipocalimab's serious adverse event rates compared favorably with other gMG therapies, while overall adverse event rates were comparable.

October 2nd, 2026

Givinostat Data Point to Delayed Loss of Ambulation, Preserved Muscle Tissue in DMD

An updated open-label extension analysis and new MRI data from the phase 3 EPIDYS trial, presented at the 2026 AANEM Annual Meeting, add to the evidence for givinostat's long-term effects on disease progression.

October 1st, 2026

LGMD Agent BBP-418 Improves Ambulation and Pulmonary Function Across Subgroups in Phase 3 FORTIFY Interim Analysis

New 12-month interim data showed functional gains with BBP-418 vs placebo, consistent benefit across genotype, age, and baseline pulmonary function subgroups, and a safety profile comparable to placebo.

October 1st, 2026

Phase 4 Study Shows Stable Motor Function in Adults With SMA on Risdiplam

Real-world 12‑month results from WeSMA, a phase 4 study, showed that oral risdiplam is well tolerated in adults with SMA, with stable motor function and consistent safety findings.

October 1st, 2026

Phase 4 Study Evaluates Transition From IVIG to Subcutaneous Efgartigimod in CIDP

A phase 4 study is evaluating whether adults with chronic inflammatory demyelinating polyneuropathy can transition from intravenous immunoglobulin to subcutaneous efgartigimod PH20 without first experiencing disease worsening.

CMSC 2020 Day 2: Anthony Feinstein, MPhil, PhD, on Diagnosing and Treating Depression in MS

Related to this article

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

FDA Accepts Fenebrutinib NDA Under Priority Review for Relapsing and Primary Progressive MS

Phase 3 PROPEL Trial to Test Imeroprubart in Generalized Myasthenia Gravis

Nipocalimab’s Safety Profile Slightly Favored Over Other Myasthenia Gravis Therapies, Indirect Comparison Shows

2026 Rachel Horne Prize Winner Sandra Vukusic, MD, PhD, on Advancing Women's Health in MS

Early Spinal Muscular Atrophy Treatment Tied to Milder Pediatric Phenotype